Pulse Explorar nav.journalClub Debates Tendencias Investigadores Revistas

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

Inicio Explorar nav.journalClub Tendencias

⌘+K

Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging | Synapse

March 1, 2018Open Access

Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imaging

SSSuzanne E. SchindlerWashington University in St. Louis JGJulia GrayHudson Institute BGBrian A. GordonWashington University in St. Louis

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

CSF biomarkers and amyloid positron emission tomography reflect different aspects of Alzheimer's disease brain pathology, and therefore, less-than-perfect correspondence is expected. Automated assays are likely to increase the utility of CSF biomarkers.

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Preguntar a la IA

Me gusta

Guardar

Compartir

Ver artículo completo

Cite This Study

Schindler et al. (Thu,) studied this question.

synapsesocial.com/papers/69d75122aa68b335b4f30f0f https://doi.org/https://doi.org/10.1016/j.jalz.2018.01.013

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Imaging and cerebrospinal fluid biomarkers in early preclinical alzheimer disease2016 · 105 citations
2Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B2004 · 4,493 citations
3The Clinical Dementia Rating (CDR)1993 · 10,007 citations
4Comparing positron emission tomography imaging and cerebrospinal fluid measurements of β‐amyloid2013 · 413 citations
5Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease2014 · 108 citations